LAVA Therapeutics NV (LAVA Therapeutics NV) EV-to-EBITDA : 0.66 (As of May. 25, 2024)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LAVA Therapeutics NV's enterprise value is $-19.03 Mil. LAVA Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-28.66 Mil. Therefore, LAVA Therapeutics NV's EV-to-EBITDA for today is 0.66.

The historical rank and industry rank for LAVA Therapeutics NV's EV-to-EBITDA or its related term are showing as below:

LVTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.83 Med: 0.98 Max: 4.51
Current: 0.66

During the past 5 years, the highest EV-to-EBITDA of LAVA Therapeutics NV was 4.51. The lowest was -20.83. And the median was 0.98.

LVTX's EV-to-EBITDA is ranked better than
75.61% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs LVTX: 0.66

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), LAVA Therapeutics NV's stock price is $2.64. LAVA Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.060. Therefore, LAVA Therapeutics NV's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

LAVA Therapeutics NV EV-to-EBITDA Historical Data

The historical data trend for LAVA Therapeutics NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV EV-to-EBITDA Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

-0.33

1.15

1.19

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBITDA	Get a 7-Day Free Trial													2.23	1.45	1.33	1.19	0.03

Competitive Comparison of LAVA Therapeutics NV's EV-to-EBITDA

For the Biotechnology subindustry, LAVA Therapeutics NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's EV-to-EBITDA falls into.

LAVA Therapeutics NV EV-to-EBITDA Calculation

LAVA Therapeutics NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	-19.030	/	-28.664
	=	0.66

LAVA Therapeutics NV's current Enterprise Value is $-19.03 Mil.
LAVA Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.66 Mil.

LAVA Therapeutics NV (NAS:LVTX) EV-to-EBITDA Explanation

LAVA Therapeutics NV's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	2.64	/	-1.060
	=	At Loss

LAVA Therapeutics NV's share price for today is $2.64.
LAVA Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.060.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

LAVA Therapeutics NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.